ORGANOGENESIS HOLDINGS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $176.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-26
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $1.00K, a 99.96% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $138.00K.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-06-30 was $0.00.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-03-31 was $37.00K, a 85.43% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $176.00K, a 94.22% decline from fiscal 2024.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $3.04M.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- ORGANOGENESIS HOLDINGS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $8.47M, a 16.26% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $139.00K derived: sum of 2 quarters · filed 2026-02-26 | $139.00K derived: sum of 3 quarters · filed 2026-02-26 | $176.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $138.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $138.00K derived: sum of 2 quarters · filed 2025-11-06 | $175.00K 10-Q · filed 2025-11-06 | $2.96M derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $37.00K 10-Q · filed 2025-08-07 | $2.83M derived: sum of 3 quarters · filed 2026-02-26 | $2.83M derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-03-31 | $37.00K 10-Q · filed 2025-05-08 | $2.83M derived: sum of 2 quarters · filed 2026-02-26 | $2.83M derived: sum of 3 quarters · filed 2026-02-26 | $2.83M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | $2.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.79M derived: sum of 2 quarters · filed 2026-02-26 | $2.79M derived: sum of 3 quarters · filed 2026-02-26 | $3.04M 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $254.00K 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $254.00K 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | $254.00K 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $67.00K derived: sum of 2 quarters · filed 2023-03-01 | $8.03M derived: sum of 3 quarters · filed 2023-03-01 | $8.47M 10-K · filed 2023-03-01 |
| 2022-09-30 | $67.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $8.03M derived: sum of 2 quarters · filed 2022-11-09 | $8.47M 10-Q · filed 2022-11-09 | $8.88M derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-06-30 | $7.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $8.41M 10-Q · filed 2022-08-09 | $8.81M derived: sum of 3 quarters · filed 2022-08-09 | $13.00M derived: sum of 4 quarters · filed 2022-08-09 |
| 2022-03-31 | $441.00K 10-Q · filed 2022-05-10 | $842.00K derived: sum of 2 quarters · filed 2022-05-10 | $5.04M derived: sum of 3 quarters · filed 2022-05-10 | $6.28M derived: sum of 4 quarters · filed 2022-05-10 |
| 2021-12-31 | $401.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $4.59M derived: sum of 2 quarters · filed 2022-03-01 | $5.84M derived: sum of 3 quarters · filed 2022-03-01 | $10.12M 10-K · filed 2022-03-01 |
| 2021-09-30 | $4.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $5.44M derived: sum of 2 quarters · filed 2021-11-09 | $9.72M 10-Q · filed 2021-11-09 | $12.85M derived: sum of 4 quarters · filed 2021-11-09 |
| 2021-06-30 | $1.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $5.53M 10-Q · filed 2021-08-09 | $8.65M derived: sum of 3 quarters · filed 2021-08-09 | $8.72M derived: sum of 4 quarters · filed 2021-08-09 |
| 2021-03-31 | $4.28M 10-Q · filed 2021-05-11 | $7.41M derived: sum of 2 quarters · filed 2021-05-11 | $7.48M derived: sum of 3 quarters · filed 2021-05-11 | $7.54M derived: sum of 4 quarters · filed 2021-05-11 |
| 2020-12-31 | $3.13M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $3.20M derived: sum of 2 quarters · filed 2021-03-16 | $3.26M derived: sum of 3 quarters · filed 2021-03-16 | $4.75M 10-K · filed 2021-03-16 |
| 2020-09-30 | $71.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $132.00K derived: sum of 2 quarters · filed 2020-11-09 | $1.62M 10-Q · filed 2020-11-09 | $1.96M derived: sum of 4 quarters · filed 2020-11-09 |
| 2020-06-30 | $61.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $1.55M 10-Q · filed 2020-08-10 | $1.89M derived: sum of 3 quarters · filed 2020-08-10 | $2.13M derived: sum of 4 quarters · filed 2020-08-10 |
| 2020-03-31 | $1.49M 10-Q · filed 2020-05-11 | $1.82M derived: sum of 2 quarters · filed 2020-05-11 | $2.07M derived: sum of 3 quarters · filed 2020-05-11 | |
| 2019-12-31 | $333.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | $578.00K derived: sum of 2 quarters · filed 2020-03-09 | $715.00K 10-K · filed 2020-03-09 | |
| 2019-09-30 | $245.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $382.00K 10-Q · filed 2019-11-12 | ||
| 2019-06-30 | $137.00K 10-Q · filed 2019-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |